As @singhgu pointed out, anything above 15% reduction above SOC is significant. I remember Dr David Packham saying that as well, if my memory serves me correct.
So we have phase 2a open trial at just under 36% above SOC. The top responders were diabetic patients.
FSGS was 29% above SOC and this is the one most were worried about.
We are going to be well over 15% above standard of care tomorrow.
GLTAH
As @singhgu pointed out, anything above 15% reduction above SOC...
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.010(2.47%) |
Mkt cap ! $217.5M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 40.5¢ | 38.5¢ | $300.6K | 765.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 188572 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 63552 | 13 |
View Market Depth
| Last trade - 15.46pm 11/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |